1. miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer
   Shihua Wu et al, 2015, BioMed Research International CrossRef
2. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor
   Yunxiang Chen et al, 2017, J Neurooncol CrossRef
3. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC
   Xiaoyuan Wang et al, 2015, Sci Rep CrossRef
4. Understanding the CREB1-miRNA feedback loop in human malignancies
   Ya-Wen Wang et al, 2016, Tumor Biol. CrossRef
5. Investigation of the association between miR-181b, Bcl-2 and LRIG1 in oral verrucous carcinoma
   Zhi-Yuan Deng et al, 2016 CrossRef
6. Protective effects of miR-25 against hypoxia/reoxygenation-induced fibrosis and apoptosis of H9c2 cells
   Qifang Liu et al, 2016 CrossRef
7. Overexpression of microRNA-141 relieves chronic constriction injury-induced neuropathic pain via targeting high-mobility group box 1
   JIZHENG ZHANG et al, 2015 CrossRef
8. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.
   Jared A Wallace et al, 2017, Blood CrossRef
9. MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia
   Marwa Nabhan et al, 2017, Gene CrossRef
10. PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
    Chao Hu et al, 2017, Sci Rep CrossRef
11. MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1
    Yun Liu et al, 2016 CrossRef
12. MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS
    Yi Xiao et al, 2017 CrossRef
13. MicroRNA-330 inhibited cell proliferation and enhanced chemosensitivity to 5-fluorouracil in colorectal cancer by directly targeting thymidylate synthase
    Weidong Xu et al, 2017 CrossRef
14. MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia
    Stefania Trino et al, 2018, IJMS CrossRef
15. High mobility group box 1 (HMGB1) acts as an “alarmin” to promote acute myeloid leukaemia progression
    Inna M. Yasinska et al, 2018, OncoImmunology CrossRef
16. Small Non-Coding RNAs in Regulation of Course and Therapeutic Efficacy in Acute Myeloid Leukemia
    Oxana V. Klimenko, 2018 CrossRef
17. Aberrant mannosylation profile and FTX/miR-342/ALG3-axis contribute to development of drug resistance in acute myeloid leukemia
    Bing Liu et al, 2018, Cell Death Dis CrossRef
18. OncomiR or antioncomiR: Role of miRNAs in Acute Myeloid Leukemia
    Chengcheng He et al, 2018, Leukemia & Lymphoma CrossRef
19. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows
    Elise Aasebø et al, 2016, Journal of Proteomics CrossRef
20. microRNA-181b suppresses the metastasis of lung cancer cells by targeting sex determining region Y-related high mobility group-box 6 (Sox6)
    You Zhou et al, 2018, Pathology - Research and Practice CrossRef
21. Overexpression of miR-758 inhibited proliferation, migration, invasion, and promoted apoptosis of non-small cell lung cancer cells by negatively regulating HMGB
    Guo-Hua Zhou et al, 2019, Biosci. Rep. CrossRef
22. Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1
    Yan Li et al, 2016, Lab Invest CrossRef
23. MicroRNAs and response to therapy in leukemia
    Hossein Sharifi et al, 2019, J Cell Biochem CrossRef
24. MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis
    Solmaz Shirjang et al, 2019, Free Radical Biology and Medicine CrossRef
25. HMGB1’in Kanser ve Tedavisiyle İlişkisi
    Eylem Taşkın Güven et al, 2019 CrossRef
26. Drug resistance-related microRNAs in hematological malignancies: Translating basic evidence into therapeutic strategies
    Lingling Xie et al, 2015, Blood Reviews CrossRef
27. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia
    Hengyou Weng et al, 2015, Cancer Genetics CrossRef
28. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules
    Kenneth K. Y. Lai et al, 2016, Tumor Biol. CrossRef
29. miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells
    Arash Nanbakhsh et al, 2015, OncoImmunology CrossRef
30. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1
    Kai-Xuan Sun et al, 2015, J Ovarian Res CrossRef
31. Clinical significance of microRNAs in chronic and acute human leukemia
    Chien-Hung Yeh et al, 2016, Mol Cancer CrossRef
32. miR-342 suppresses the proliferation and invasion of acute myeloid leukemia by targeting Naa10p
    Haiyan Wang et al, 2019, Artificial Cells, Nanomedicine, and Biotechnology CrossRef
33. The multi-factorial nature of clinical multidrug resistance in cancer
    Yehuda G. Assaraf et al, 2019, Drug Resistance Updates CrossRef
34. MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2
    Shun Ke et al, 2017, Int J Hematol CrossRef
35. MicroRNA: an important regulator in acute myeloid leukemia.
    Xiaman Wang et al, 2017, Cell Biol Int CrossRef
36. Altered expression of miR-181 affects cell fate and targets drug resistance-related mechanisms
    Cornelia Braicu et al, 2019, Molecular Aspects of Medicine CrossRef
37. Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments
    Kenneth K.W. To et al, 2019, Expert Opinion on Drug Discovery CrossRef
38. microRNA-181 serves as a dual-role regulator in the development of human cancers
    Tayebeh Rezaei et al, 2019, Free Radical Biology and Medicine CrossRef
39. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation
    Katja Seipel et al, 2020, Leukemia Research CrossRef
40. Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance
    Ajaz A. Bhat et al, 2020, Mol Cancer CrossRef
41. The renoprotective effect of curcumin against cisplatin-induced acute kidney injury in mice: involvement of miR-181a/PTEN axis
    Si-Jia Huang et al, 2020, Renal Failure CrossRef
42. LncRNA MEG3 contributes to drug resistance in acute myeloid leukemia by positively regulating ALG9 through sponging miR‐155
    Yanan Yu et al, 2020, Int J Lab Hematol CrossRef
43. miRNAs in acute myeloid leukemia
    Qiong Liao et al, 2017, Oncotarget CrossRef
44. MicroRNA-181 as a prognostic biomarker for survival in acute myeloid leukemia: a meta-analysis
    Qiang Guo et al, 2017, Oncotarget CrossRef
45. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia
    Lifen Zhao et al, 2016, Oncotarget CrossRef
46. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer
    Xiaoping Liu et al, 2015, Oncotarget CrossRef
47. Noncoding RNAs: the shot callers in tumor immune escape
    Lei Liu et al, 2020, Sig Transduct Target Ther CrossRef
48. High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies
    Shunling Yuan et al, 2020, J Hematol Oncol CrossRef
49. Autophagy-mediating microRNAs in cancer chemoresistance
    Yuanming Jing et al, 2020, Cell Biol Toxicol CrossRef
50. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers
    Anita Alizadeh et al, 2020, Gene CrossRef
51. Chronic stress promotes acute myeloid leukemia progression through HMGB1/NLRP3/IL-1β signaling pathway
    Na Liu et al, 2021, J Mol Med CrossRef
52. CircCSNK1G3 up‐regulates miR‐181b to promote growth and metastasis via TIMP3‐mediated epithelial to mesenchymal transitions in renal cell carcinoma
    Wen Li et al, 2021, J. Cell. Mol. Med. CrossRef
53. LINC00665 promotes the progression of acute myeloid leukemia by regulating the miR-4458/DOCK1 pathway
    Xiaoyu Yang et al, 2021, Sci Rep CrossRef
54. miRNAs Mediated Drug Resistance in Hematological Malignancies
    Sara Peixoto da Silva et al, 2021, Seminars in Cancer Biology CrossRef
55. Mitochondrial metabolism as a target for acute myeloid leukemia treatment
    Svetlana B. Panina et al, 2021, Cancer Metab CrossRef
56. Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
    Guadalupe Rosario Fajardo-Orduña et al, 2021, IJMS CrossRef
57. Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome
    María Julia Lamberti et al, 2021, Cancers CrossRef
58. Circadian rhythm genes in cancer: insight into their functions and regulation involving noncoding RNAs
    Indrani Ray et al, 2021, Chronobiology International CrossRef
59. MicroRNA-181b Inhibits Inflammatory Response and Reduces Myocardial Injury in Sepsis by Downregulating HMGB1
    Lan Ling et al, 2021, Inflammation CrossRef
60. miR-34b Targets HSF1 to Suppress Cell Survival in Acute Myeloid Leukemia
    Gangcan Li et al, 2016, oncol res CrossRef
61. Small Non-Coding RNAs in Leukemia
    Veronica Balatti et al, 2022, Cancers CrossRef
62. Exosomes and MicroRNAs in Biomedical Science
    Hamed Mirzaei et al, 2022, Synthesis Lectures on Biomedical Engineering CrossRef
63. microRNA expression in acute myeloid leukaemia: New targets for therapy?
    Daniel Fletcher et al, 2022, eJHaem CrossRef
64. MicroRNAs in Cancer
    Hamed Mirzaei et al, 2022 CrossRef
65. Role of post-transcriptional gene regulation in hematological malignancies
    Hafiz M. Ahmad, 2022 CrossRef
66. MicroRNA‑181b‑5p insufficiency predicts treatment response failure risk and unfavorable event‑free survival as well as overall survival in acute myeloid leukemia patients
    Huina Lu et al, 2022, Oncol Lett CrossRef
67. Non-coding RNA-related antitumor mechanisms of marine-derived agents
    Zhixia Zhou et al, 2022, Front. Pharmacol. CrossRef
68. The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia
    Mohammad H. Ghazimoradi et al, 2023, Genes CrossRef
69. M2 Macrophage‐Derived sEV Regulate Pro‐Inflammatory CCR2 + Macrophage Subpopulations to Favor Post‐AMI Cardiac Repair
    Lan Li et al, 2023, Advanced Science CrossRef
70. Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways
    Atefe Rahmati et al, 2024, Ann Hematol CrossRef
71. Use of extracellular vesicle microRNA profiles in patients with acute myeloid leukemia for the identification of novel biomarkers
    Ka-Won Kang et al, 2024, PLoS ONE CrossRef
72. Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view
    Fatemeh Ebadi Meinag et al, 2024, Funct Integr Genomics CrossRef
73. MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia
    Kun Wu et al, 2024, Int J Oncol CrossRef
74. MicroRNAs and other noncoding RNA species in diagnostics, prognostics and therapy response of blood cancers
    D. Ivovic et al, 2025 CrossRef
75. The modulation of immune cell death in connection to microRNAs and natural products
    Ya-Ting Chuang et al, 2024, Front. Immunol. CrossRef
76. Investigating Apoptotic Effect through Blocking miR-181b and miR-222 Using LNA-anti-miRNA in HL-60 Cell Line: Strategies to Improve Hematopoietic Stem Cell Transplantation
    Mahdiyar Iravani Saadi et al, 2024, IJOTM CrossRef